Scenarios that move NVS
Novartis AG Common Stock
Scenarios that move NVS: 14 analyses, 5 positive, 9 negative.
- · Roche reports positive Phase III eye drug data, FDA accepts BLA — ▼ · impact -39 · confidence medium · horizon quarters
- · argenx meets primary endpoint in Phase II celiac disease study — ▲ · impact +26 · confidence low · horizon quarters
- · Novartis acquires Abogen in $7.8B RNA therapeutics deal — ▲ · impact +44 · confidence medium · horizon weeks
- · Genmab and AbbVie report positive epcoritamab lymphoma trial results — ▼ · impact -34 · confidence medium · horizon quarters
- · uniQure plunges after additional Huntington's disease study data — ▲ · impact +18 · confidence low · horizon quarters
- · Lilly reports strong weight loss results for new drug — ▼ · impact -15 · confidence low · horizon quarters
- · DBV Technologies files FDA BLA for VIASKIN Peanut patch — ▼ · impact -18 · confidence high · horizon quarters
- · Kodiak Sciences shares soar 178% on positive wet AMD data — ▼ · impact -50 · confidence low · horizon quarters
- · ADARx Pharmaceuticals prices upsized $446.3 million initial public offering — ▼ · impact -15 · confidence low · horizon quarters
- · Ionis reports positive late-stage results for two partnered drugs — ▲ · impact +56 · confidence medium · horizon weeks
- · Oruka Therapeutics reports positive week 28 ORKA-001 trial data — ▼ · impact -23 · confidence medium · horizon quarters
- · AstraZeneca's Etcamah fails late-stage study in first-line breast cancer — ▲ · impact +35 · confidence high · horizon quarters
- · FDA approves Isembyld for spinal muscular atrophy treatment — ▼ · impact -47 · confidence medium · horizon weeks
- · Amgen shares fall after Novartis' Pelacarsen misses Phase III goal — ▼ · impact -75 · confidence high · horizon immediate